Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C23H17ClN4O4S and a molecular weight of approximately 480.92 g/mol[1][4]. It belongs to the class of benzanilides, specifically anilide derivatives containing sulfonamide and pyridine moieties[6]. The IUPAC name is N-{2-[ (5-chloropyridin‑2‑yl )sulfamoyl ]phenyl }‑4‑( 2‑oxo‑1, dihydropyridin- 1- y l )benzamide[1][6]. There are no known approved medical indications or clinical trials associated with this compound as of June 2025, and it appears to be primarily used in research settings as an experimental chemical probe or tool compound[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2-(((5-chloro-2-pyridinyl)amino)sulfonyl)phenyl)-4-(2-oxo-1(2H)-pyridinyl)benzamide.